公司资料
Lantheus Holdings, Inc. 股价、新闻与催化剂
- 股票代码:
- LNTH
- 交易所:
- NASDAQ
- 行业:
- Radiopharmaceuticals, Oncology
- 所在地:
- United States
股票表现
100.91 USD (-0.04%)
收盘价
最后更新: 2026年8月17日
—
市值
股价为何变动
As of Aug 17, 2026, LNTH was little changed and closed at $100.91. No new same-company headline was identified in the current news window.
公司概览
Radiopharmaceutical-Focused Platform
Lantheus is a radiopharmaceutical-focused company that develops and commercializes diagnostic imaging agents and targeted radiotherapeutics. Its “Find, Fight and Follow” strategy spans disease detection, treatment and longitudinal monitoring, supported by approximately 70 years of experience in radiopharmaceutical development and supply.
PSMA PET Imaging Franchise
PYLARIFY is an F-18 prostate-specific membrane antigen PET imaging agent used to detect PSMA-positive lesions in patients with prostate cancer. It is Lantheus’ largest commercial product and anchors the company’s oncology radiodiagnostic business. PYLARIFY TruVu is a newly approved formulation designed to improve manufacturing efficiency and supply flexibility across the company’s PET manufacturing network.
Neuroendocrine Tumor Portfolio
LNTH-2501 is an investigational gallium-68 edotreotide PET imaging kit for localizing somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. PNT2003 is a lutetium-177 dotatate radiotherapeutic that has received tentative FDA approval and is intended to become the first radioequivalent treatment for gastroenteropancreatic neuroendocrine tumors, subject to final approval and resolution of applicable patent matters.
Alzheimer’s Disease Imaging
Lantheus is expanding its neurology business through an Alzheimer’s disease imaging portfolio led commercially by Neuraceq. Additional assets, including MK-6240 and NAV-4694, support the company’s broader strategy of supplying PET imaging tools for the detection and characterization of Alzheimer’s-related pathology in clinical care and therapeutic development.
Cardiac Ultrasound Imaging
DEFINITY is an ultrasound-enhancing agent used to improve visualization during echocardiography. The product provides Lantheus with an established cardiology franchise outside radiopharmaceutical imaging and contributes recurring demand through routine diagnostic use.
Focused PET and Theranostics Strategy
Lantheus divested its legacy SPECT business to concentrate resources on PET radiodiagnostics and simplify its operating model. The company is prioritizing radiodiagnostic commercialization, manufacturing-network expansion and Alzheimer’s imaging while evaluating value-maximizing development or partnership paths for its radiotherapeutic assets.
未来催化剂
- FDA action on LNTH-2501 for somatostatin receptor-positive neuroendocrine tumor imaging expected by June 29, 2026.
- Phased geographic launch of PYLARIFY TruVu planned to begin in the fourth quarter of 2026.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。